Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.38 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.38 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CCKAR | P32238 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414684 | 0.96 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL1115756 | 0.96 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL29414377 | 0.96 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL837924 | 0.96 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL42287 | 0.82 | CA12 (0.54) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL29478385 | 0.82 | CA12 (0.54) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL42286 | 0.82 | CA12 (0.54) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL298855 | 0.82 | CA12 (0.54) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL409050 | 0.82 | CA12 (0.54) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL29367675 | 0.82 | CA12 (0.54) | ALDH1A1MEN1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228985-A1 | MODIFIED SEED OIL CONTENT IN PLANTS | PIONEER HI-BRED INTERNATIONAL, INC (US) | 2024-07-11 | — | — | US | claimed |
| CN-116953228-A | Method and reagent for identifying antibody combined with mutant antigen | 广东菲鹏生物有限公司 | 2023-10-27 | — | — | CN | claimed |
| WO-2022246387-A1 | MODIFIED SEED OIL CONTENT IN PLANTS | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2022-11-24 | — | — | WO | claimed |
| US-20220186258-A1 | MODIFIED AAV VECTORS THAT DAMPEN THE HUMORAL IMMUNE RESPONSE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-06-16 | — | — | US | claimed |
| US-20210371472-A1 | INFLUENZA VIRUS HEMAGGLUTININ MUTANTS | ARAMIS BIOTECHNOLOGIES INC. (CA) | 2021-12-02 | — | — | US | claimed |
| US-20210340184-A1 | INFLUENZA VIRUS HEMAGGLUTINIIN MUTANTS | ARAMIS BIOTECHNOLOGIES INC. (CA) | 2021-11-04 | — | — | US | claimed |
| US-20210221853-A1 | INFLUENZA VIRUS HEMAGGLUTININ MUTANTS | ARAMIS BIOTECHNOLOGIES INC. (CA) | 2021-07-22 | — | — | US | claimed |
| EP-3814508-A1 | INFLUENZA VIRUS HEMAGGLUTININ MUTANTS | Medicago Inc. (CA) | 2021-05-05 | — | — | EP | claimed |
| EP-3814507-A1 | INFLUENZA VIRUS HEMAGGLUTININ MUTANTS | Medicago Inc. (CA) | 2021-05-05 | — | — | EP | claimed |
| EP-3814509-A1 | INFLUENZA VIRUS HEMAGGLUTININ MUTANTS | Medicago Inc. (CA) | 2021-05-05 | — | — | EP | claimed |
| WO-2007074456-A2 | INHIBITION OF CXCR4 AND/OR CELL MOTILITY BY PHENYLALANINE, CYSTEINE OR PEPTIDES CONTAINING SAID AMINOACIDS | YEDA RESEARCH AND DEVELOPMENT CO.LTD. (IL) | 2007-07-05 | — | — | WO | claimed |
| JP-2007511536-A | — | — | 2007-05-10 | — | — | JP | claimed |
| CN-1295335-C | A gene coding for a protein regulating aureobasidin sensitivity | TAKARA SHUZO CO (JP) | 2007-01-17 | — | — | CN | claimed |
| EP-1708690-A2 | TREATMENT OF PHENYLKETONURIAS WITH BH4 | BioMarin Pharmaceutical Inc. (US) | 2006-10-11 | — | — | EP | claimed |
| US-20060040946-A1 | Methods and compositions for the treatment of metabolic disorders | BIOMARIN PHARMACEUTICAL INC. (US) | 2006-02-23 | — | — | US | claimed |
| WO-2005049000-A2 | TREATMENT OF PHENYLKETONURIAS WITH BH4 | BIOMARIN PHARMACEUTICAL INC. (US) | 2005-06-02 | — | — | WO | claimed |
| US-20040131609-A1 | Ultra high affinity neutralizing antibodies | APPLIED MOLECULAR EVOLUTION, INCORPORATED | 2004-07-08 | — | — | US | claimed |
| EP-1265928-A1 | ULTRA HIGH AFFINITY NEUTRALIZING ANTIBODIES | MEDIMMUNE, INC. (US) | 2002-12-18 | — | — | EP | claimed |
| US-20020164326-A1 | Ultra high affinity neutralizing antibodies | MEDIMMUNE, LLC | 2002-11-07 | — | — | US | claimed |
| WO-2001055217-A1 | ULTRA HIGH AFFINITY NEUTRALIZING ANTIBODIES | MEDIMMUNE, INC. (US) | 2001-08-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040946-A1 | Methods and compositions for the treatment of metabolic disorders | PAH, BHMT, FAH | ALDH1A1 1048/4885MEN1 2539/4885KMT2A 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.